A promising new pilot study from Italy, set to be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, is shedding light on an unconventional approach to cancer care: short-term fasting. Researchers have found that for patients undergoing treatment for high-grade serous ovarian cancer (HGSOC), fasting before and after chemotherapy cycles may significantly reduce insulin levels and improve the body’s response to life-saving medication.
As the medical community looks for ways to optimize existing treatment protocols without adding the toxicity of new drugs, this study offers a compelling, low-cost, and accessible strategy that warrants further investigation.
The Core Findings: A Breakthrough in Supportive Care
The study, conducted in Rome, Italy, followed 36 patients diagnosed with stage III or IV HGSOC. The trial aimed to test the hypothesis that metabolic manipulation—specifically, the reduction of insulin—could enhance the efficacy of traditional chemotherapy.
The results were striking: participants who adhered to a strict, short-term fasting protocol before and after their chemotherapy sessions exhibited lower insulin levels compared to those who maintained a regular diet. Furthermore, the fasting group showed improved pathological responses to treatment and extended progression-free survival.
Because insulin is a hormone that can theoretically promote cancer cell growth and interfere with the mechanisms by which chemotherapy kills tumor cells, the reduction of this hormone appears to create a more hostile environment for the cancer, while potentially protecting healthy cells.
The Landscape of High-Grade Serous Ovarian Cancer
To understand the significance of this research, one must first understand the clinical reality of HGSOC. Ovarian cancer remains one of the most lethal malignancies among the female reproductive organs. While not as common as breast or lung cancer, its high mortality rate is driven largely by the fact that it is frequently diagnosed only after reaching an advanced stage.
HGSOC represents the most aggressive and common form of ovarian cancer, accounting for a staggering 70% to 80% of all ovarian cancer-related deaths. The standard of care for advanced cases typically involves a combination of surgery to debulk the tumor and neoadjuvant chemotherapy—treatment administered before surgery to shrink the tumor mass.
Despite aggressive medical intervention, the prognosis for many patients remains guarded. A recurring challenge in oncology is that for the majority of patients who complete initial treatment, the cancer returns within two years. This "treatment-refractory" nature of ovarian cancer has pushed researchers to look beyond traditional pharmaceutical avenues, exploring lifestyle and metabolic interventions that might improve the odds of long-term remission.
Chronology of the Clinical Trial
The pilot study was meticulously structured to ensure patient safety and data integrity while testing the fasting intervention. The trial followed a clear timeline for the 36 participants, all of whom were in relatively good general health with an average age of 62.
1. The Enrollment Phase
The researchers recruited 36 patients in Rome, all diagnosed with advanced (Stage III or IV) HGSOC. Every participant was scheduled to receive three rounds of standard carboplatin and paclitaxel chemotherapy prior to their primary surgery.
2. Randomization and Protocol Implementation
Upon enrollment, participants were randomly assigned to one of two groups:
- The Control Group (18 patients): These individuals maintained their regular dietary habits throughout the course of their chemotherapy treatment.
- The Fasting Group (18 patients): These individuals adhered to a strict 60-hour fasting window for every chemotherapy cycle—specifically, 36 hours before and 24 hours after each infusion.
3. The Dietary Constraints
The fasting group was not entirely deprived of nutrients. To ensure safety and prevent muscle wasting, they were permitted:
- Unlimited water and herbal tea.
- Up to 2 liters of vegetable juice per day.
- Small amounts of light vegetable broth.
- A strict caloric cap: No more than 350 calories per 24-hour period during the fasting windows.
4. Monitoring and Evaluation
Between the chemotherapy sessions, patients in the fasting group returned to a regular, unrestricted diet. Researchers monitored blood markers, insulin levels, and chemotherapy side effects throughout the study. Notably, every single participant in the fasting group completed the trial, suggesting that the protocol, while challenging, is feasible for patients in good physical condition.
Supporting Data and Clinical Observations
One of the primary concerns when introducing fasting to cancer patients is the potential for increased toxicity. Chemotherapy is physically demanding, and the risk of malnutrition or low blood cell counts (neutropenia/anemia) is a constant concern for oncologists.
However, the study provided reassuring data. The side effects observed in the fasting group were consistent with those of the control group. Both cohorts experienced similar rates of low blood cell counts and reduced hemoglobin, which are standard, expected complications of platinum-based chemotherapy.
By demonstrating that fasting did not exacerbate the adverse effects of the treatment, the researchers have cleared a major hurdle for future clinical implementation. The reduction in insulin levels was the physiological "smoking gun," suggesting that the metabolic state induced by the fast is indeed changing the internal environment in which the chemotherapy operates.
Expert Perspectives: Why This Matters
Eleonora Teplinsky, MD, Head of Breast and Gynecologic Medical Oncology at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO Expert, emphasizes that while the study is small, it represents a pivotal shift in how we think about "supportive" care.
"Fasting during chemotherapy is an area of growing research interest," Dr. Teplinsky stated. "This pilot randomized clinical trial showed that short-term fasting… led to a reduction in insulin levels… and improved pathologic response and progression-free survival."
Dr. Teplinsky noted that the study supports earlier, smaller-scale data points and underscores a critical, low-cost area of cancer research. "While this is a small study, the findings are encouraging," she added, calling for larger clinical trials to validate these results and establish standardized protocols.
Lead study author Dr. Claudia Marchetti echoed this sentiment, emphasizing the "urgent need for safe, low-cost, and easily implementable strategies" to combat the poor outcomes associated with advanced ovarian cancer. In a global health landscape where the cost of novel cancer drugs continues to skyrocket, a non-pharmacological, patient-led intervention like fasting offers a unique and egalitarian path forward.
Implications for the Future of Oncology
The implications of this research extend far beyond ovarian cancer. If metabolic manipulation via fasting can improve the efficacy of chemotherapy in HGSOC, it may eventually be tested in other solid tumor cancers where insulin signaling plays a role in disease progression.
1. A New Paradigm in Integrative Oncology
Historically, oncology has been siloed from nutrition science. This study bridges that gap, suggesting that "when" we eat might be just as important as "what" we eat during cancer treatment. By timing nutritional intake around the administration of cytotoxic drugs, physicians may be able to "prime" the body to be more receptive to treatment.
2. The Need for Larger Trials
The scientific community is notoriously cautious. A pilot study of 36 people is insufficient to change clinical guidelines. The next step, as indicated by the researchers, is a larger, multi-center randomized controlled trial. These future studies will need to investigate:
- Long-term survival: Does the improved response translate into longer overall survival rates?
- Quality of Life (QoL): How does fasting affect the psychological well-being and energy levels of patients in the long term?
- Biological Mechanisms: Does fasting specifically protect healthy immune cells while sensitizing tumor cells?
3. Patient Safety and Clinical Guidance
Crucially, patients are warned not to attempt aggressive fasting protocols without direct medical supervision. Oncology patients are at risk for metabolic imbalances, and any change to caloric intake must be monitored by a clinical team to prevent dangerous deficiencies or interference with medications.
Conclusion: A Promising Path Forward
The research from the Fondazione Policlinico Universitario Agostino Gemelli in Rome serves as a beacon of hope for patients facing a difficult diagnosis. By focusing on the body’s metabolic response to cancer treatment, scientists are opening doors to therapies that are not only effective but also accessible to all patients, regardless of their financial resources.
As the findings are presented at the 2026 ASCO Annual Meeting in Chicago, the oncology community will be watching closely. While much work remains to be done, the integration of short-term fasting into cancer care protocols represents a potential paradigm shift—one that prioritizes metabolic health as a powerful ally in the fight against cancer.
For now, the message is one of cautious optimism: simple, well-timed dietary changes may eventually play a role in turning the tide against one of the most challenging cancers in modern medicine.
About the Author
